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INTRODUCTION
Radiation therapy plays a critical role in the treatment of
cervix cancer (1). Most cases of locally advanced stage dis-
ease and patients with poor general conditions receive radia-
tion therapy with curative intent. The response to radiation
in the cervix cancer is affected by several factors, and among
them, hypoxia is one of the key determinant (2). Hypoxia is
known to stimulate vascular endothelial growth factor (VEGF)
in cervix cancer cells (3) which stimulates tumor angiogenesis
(4) and enhances radio-resistance by targeting vascular endo-
thelial cells (5). Also the induction of VEGF by ionizing radia-
tion is proposed to favor tumor survival by increasing the
radioresistance of tumor vascular endothelium (6). Thus the
VEGF expression is suggested to have negative influence on
patient’s survival treated with radiation therapy. There are
several reports supporting the prognostic role of VEGF expres-
sion in cervix cancer (7-9). These reports suggest possible rela-
tionship between VEGF expression and radiation response
of cervix cancer. To investigate the relationship between VEGF
expression and radiotherapy outcome in cervix cancer, we
analyzed forty-two squamous cell cervix cancer patients treat-
ed with radiation therapy alone.
MATERIALS AND METHODS
Patient characteristics
The study involved 42 squamous cell cervix cancer patients
with available paraffin blocks among the 82 patients who
were treated with curative radiation therapy over the period
from 1994 to 2001 in Eulji University Hospital in Korea.
The histopathologic features of the surgical specimens were
classified according to the WHO criteria and the patients
were staged according to International Federation of Obstet-
rics and Gynecology. The staging evaluation included phys-
ical examination, tissue diagnosis, cystoscopy, sigmoidoscopy,
chest radiography, MRI of the abdomen and pelvis and lab-
oratory studies. The follow-up information was based on the
last clinical examination. 
The number of patients of stage IB, II and III&IV were 13,
23 and 6, respectively. Median age of the patients was 62 yr
(range 28-83). 23 patients had tumor size 4 cm or more and
19 patients had less than 4 cm. Patients with pelvic lymph
node on CT or MRI were 20 and patients with parametrial
invasion were 23. Median follow-up duration was 39 months
(range 3-88). 
All patients received at least 45 Gy of radiation therapy
in pelvis (range 45-63). Radiation was delivered for five days
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The Prognostic Effect of VEGF Expression in Squamous Cell Carcinoma
of the Cervix Treated with Radiation Therapy Alone
We investigated the relationship between vascular endothelial growth factor (VEGF)
expression and clinical outcome in squamous cell carcinoma of the cervix treated
with radiotherapy alone. The immunohistochemical study was performed for forty-
two paraffin embedded specimens with anti-VEGF mouse monoclonal antibody.
Staining was defined as positive for VEGF when more than 10% of the tumor cells
were stained from 500 cells counted. Positive VEGF expression was observed in
twenty-one among forty-two patients. VEGF expression according to stage (p=0.101),
lymph node status (p=0.621), parametrial invasion (p=0.268), and age (p=0.5) re-
vealed no significant difference. But the VEGF expression was significantly higher
in tumors larger than 4 cm (p=0.031). Five year survival rates according to VEGF
expression status were 89% for VEGF negative group and 47% for VEGF positive
group (p=0.02). FIGO stage (p=0.007), tumor size (p=0.025) and the duration of
external beam radiation therapy (p=0.006) were also significant prognostic factors
for overall survival. We suggest that VEGF expression may be a prognotic factor
of the cervix cancer patients treated with radiation therapy alone. 
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a week with daily fractions of 1.8 to 2 Gy by 6MV photon.
Median duration of external radiation therapy was 43 days
(range 30-71). Low dose rate brachytherapy was performed
in 28 patients, and median dose to point A was 83 Gy (range
64-104.9).
Immunohistochemical staining
Immunohistochemical staining was performed on archival
biopsy material in paraffin block. The microscopic slides were
obtained from each block by cutting 5  m sections with a
microtome. The anti-VEGF mouse monoclonal antibody
(Oncogene, Boston, MA, U.S.A. diluted 1:10) was used as
primary antibody. Antibody binding was detected with a
labelled streptavidin biotin (LSAB) kit (ScyTek, Logan, UT,
U.S.A.). Antibody binding was done at room temperature for
30 min. After washing, the sections were incubated at room
temperature for 30 min with a peroxidase labelled polymer
conjugated to goat-anti-rabbit immunoglobulins in Tris-HCl
buffer. A substrate-chromogen solution containing 3-amino-
9-ethylcarbazole was applied for 5 min. After rinsing in water,
the slides were lightly counter-stained with hematoxylin and
eosin, dehydrated and mounted. Two pathologists blinded to
the treatment of the patients and the outcome interpreted the
slides with light microscope. The results were reported as the
percent of tumor cells with positive nuclear staining, regard-
less of the intensity of the stain. Staining was defined as posi-
tive when more than 10% of the tumor cells were stained from
500 cells counted. We used placental tissue as positive control
and same reagents except the primary antibody for negative
control. All slides were evaluated for immunohistochemical
staining without knowledge of the clinical outcome.
Statistical methods
A statistical analysis was performed by using SPSS 10.0
for Windows. Survival was analyzed by Kaplan Meier method
and compared by log-rank test for univariate analysis. For
multivariate analysis, bivariate log-rank test and Cox regres-
sion analysis were performed. Survival duration was counted
from the first day of radiation therapy to the last day of the
follow-up or death. To compare clinical factors and staining
results, the chi-square test was used. Probability value <0.05
were considered statistically significant.
RESULTS
Positive VEGF expression was observed in 21 (50%) of the
total of 42 patients. Statistical evaluation of VEGF expression
according to stage, lymph node status, parametrial invasion,
and age revealed no significant difference. But tumors with
4 cm or more showed significantly high VEGF positive rate
(71%) in comparison with tumors less than 4 cm (38%) (p=
0.031). All the four patients who died of metastatic disease
were VEGF positive. On the contrary, among the nine patients
who died with local progression, only one patient was posi-
tive for VEGF expression (p=0.008). Correlations between
VEGF expression and various clinical features are listed in
Table 1.
Five year survival rate for stage IB, II and III & IV were
89%, 67%, and 22% respectively (p=0.007) (Fig. 1). Five
Characteristics p value
No. of VEGF negative/positive 
(% of positive patients)
Stage
IB (n=13) 9/4 (30.7%) 0.101
II (n=23) 10/13 (56.5%)
III&IV (n=6) 2/4 (50%)
Tumor size
<4 cm (n=19) 13/6 (31.5%) 0.031
>4 cm (n=23) 8/15 (65.2%)
Lymph node metastasis
No (n=22) 11/11 (50%) 0.621
Yes (n=20) 10/10 (50%)
Parametrial invasion
No (n=19) 11/8 (42.1%) 0.268
Yes (n=23) 10/13 (56.5%)
Age (yr)
<60 (n=19) 10/9 (47.3%) 0.5
≥60 (n=23) 11/12 (52.1%)
Total number of negative/ 21/21 (50%)
positive tumors
Table 1. The relationship between VEGF expression status and
other clinical parameters
No. of patients p value
5 yr overall 
survival rate (%)
Stage
IB 13 89 0.007
II 23 67
III&IV 6 22
Tumor size
<4 cm 19 83 0.025
≥4 cm 23 53
Lymph node metastasis
No 22 68 0.8
Yes 20 67
Parametrial invasion
No 19 80 0.213
Yes 23 57
Age (yr)
<60 19 73 0.362
≥60 23 60
Radiotherapy duration (days)
<50 27 82 0.006
≥50 15 43
VEGF
No 21 89 0.02
Yes 21 47
Table 2. Univariate log-rank analysis of prognostic factors for car-
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year survival rate of the patients with tumor size less than 4
cm was 83% and patients with tumor size more than 4 cm
was 53% (p=0.025) (Fig. 2). Five year survival rate accord-
ing to VEGF expression status were 89% for VEGF negative
group and 47% for VEGF positive group (p=0.02) (Fig. 3).
Five year survival rate of the patients without detectable
lymph node in pelvic CT or MRI was 68% and the patients
with positive lymph node was 67% (p=0.8). Among the 13
patients who died, 4 were with metastatic disease and 9 were
with local recurrence. The results of univariate log-rank analy-
sis of the relationship between clinical findings and survival
are listed in Table 2.
Bivariate log-rank test were carried out in order to test the
independence of VEGF expression from other prognostic fac-
tors. The significance of VEGF expression remained after
stratifying other prognostic factors such as lymph node meta-
stasis, parametrial invasion and age in bivariate log-rank anal-
ysis. After stratifying significant prognostic factors in univari-
ate analysis such as stage, tumor size, and radiation therapy
duration, bivariate log-rank test did not show statistical sig-
nificance (Table 3). Cox multiple regression analysis was
performed to evaluate the significance of prognostic factors
(Table 4). FIGO stage (p=0.021) and radiation therapy dura-
tion (p=0.013) were independent prognostic factors for overall
survival but tumor size and VEGF expression were not statis-
tically significant in multiple regression analysis.
DISCUSSION
There are several reports supporting the prognostic role of
VEGF expression in cervix cancer but the number of studies
about VEGF expression and primary radiotherapy outcome
is limited. Loncaster et al. (8) reported that the survival rate
was markedly decreased and the distant metastasis rate was
increased significantly for the patients with high VEGF ex-
pression. According to this report, the VEGF expression was
the most potent prognostic factor in multivariate analysis. But
the limitation of this study is that they included only bulky
stage IB and advanced stage patients to evaluate the relation-
ship between VEGF expression and disease stage, tumor dif-
ferentiation, patient age and tumor radiosensitivity (SF2) but
not tumor size. Cheng et al. (9) reported that the median
VEGF concentrations in cervical carcinoma was 118 pg/mL
for tumor size less than 4 cm and 1,030 pg/mL for the larger
tumors which shows about 9 fold difference between them.
It has been reported that serum VEGF was also higher in
larger tumors (10). So even in the same stage, it is certain that
the tumor size affects VEGF concentration and expression
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Fig. 1. Survival curves according to stage. Five year overall survival
rate is 89% for stage IB (solid line, n=13), 67% for stage II (dot line,
n=23) and 22% for stage III&IV (dashed line, n=6) (p=0.007). 
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Fig. 2. Survival curves according to tumor size. Five year survival
rate is 83% for the tumors of less than 4 cm (solid line, n=19) and
53% for the tumors 4 cm or more (dot line, n=23) (p=0.0025).
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Fig. 3. Survival of the patients grouped according to VEGF: posi-
tive (dot line, n=21) and negative (solid line, n=21). Five year over-
all survival rate of VEGF negative group was 89% and 47% for
positive group (p=0.02).696 J.-O. Kang, S.-E. Hong
in immunohistochemical study. 
There are some debates about the relationship between
tumor size and VEGF expression status. Lee et al. (7) report-
ed that the VEGF expression did not have relationship with
tumor size. But in this study, all of ten adenocarcinoma pa-
tients among total 118 patients belonged to the VEGF low
expression group. But VEGF expression frequency and inten-
sity is usually higher in adeocarcinoma than in squamous cell
carcinoma of the cervix (11-13). Thus the results of Lee et al.
(7) showed unusual expression pattern between adenocarci-
noma and squamous cell carcinoma so that we question about
the possibility of the unusual ten adenocarcinoma patients dis-
turbed the VEGF expression results in this study. In our study,
VEGF expression was significantly higher in tumors larger
than 4 cm than in smaller tumors (65% vs. 31%, p=0.031)
and also five-year overall survival rate was significantly higher
in VEGF negative group (89% vs. 47%, p=0.002). We sug-
gest that the VEGF expression is associated with larger tumor
size.
The association between VEGF expression and other clinical
findings is controversial. In our study, VEGF expression did
not show relationship with clinical factors such as stage, age,
lymph node status and parametrial invasion. These results
are similar with Loncaster et al. (8), in which there was no
correlation between VEGF expression and disease stage, pati-
ent age. They did not analyze the relationship between VEGF
and lymph node status and parametrial invasion. But Cheng
et al. (9) reported that tumors with overexpressed VEGF had
higher incidence of deep stromal invasion, parametrial inva-
sion and lymph node metastasis. Our study had limitations
that the clinical findings were dependent only on the pelvic
examination and pelvic MRI findings because all of the patient
received primary radiotherapy and did not receive surgical
operations to confirm pathologic findings. We need further
investigation about this aspect. 
The relationship between VEGF status and disease progres-
sion in the previous reports was not in accordance. Bachtiary
et al. (10) reported that in patients undergoing primary radio-
therapy for cervical cancer, all four patients with local failure
had VEGF levels >244 pg/mL, whereas 11 of 19 patients with
complete response had serum VEGF levels <244 pg/mL. They
suggested that high serum VEGF concentration is associated
with impaired response to radiotherapy as well as shortened
progression-free survival. Meanwhile, Longcaster et al. (8)
reported that high VEGF expression was associated with over-
all survival and metastasis-free survival, but not local control.
They suggested that VEGF expression is primarily reflecting
the metastatic potential of a tumor rather than response to
radiotherapy. The suggestion that VEGF expression is asso-
ciated with metastatic potential is supported by Ferrara (14)
who demonstrated that VEGF promotes metastatic spread by
increasing blood vessel permeability. We did not compare
survivals according to the cause of death because of the small
number of metastatic death (n=4). However, all of the four
patients who died with metastatic disease were positive for
VEGF expression. On the contrary, among the nine patients
who died with local progression, only one patient was positive
for VEGF expression. Our results support the possibility that
the VEGF expression is related with metastatic potential rather
than local progression. 
Our study showed that the positive VEGF expression was
significantly related with poor prognostic factors in univariate
analysis. The significance of VEGF on the prognosis remained
even with the bivariate analysis stratifying clinical factors such
as lymph node metastasis, parametrial invasion and age. But
in bivariate analysis stratifying previous prognostic factors
such as stage, tumor size and radiation therapy duration, the
VEGF expression did not show statistical significance. The
number of stage III&IV patients (n=6) was too small to be
stratified so that the p value (p=0.886) was far from statisti-
cal significance. Though the results of bivariate analysis strat-
ifying the tumor size (p=0.085) and the radiation therapy dura-
tion (p=0.089) did not reach statistical significance, we sug-
gest further analysis is needed because tumor size was signifi-
cantly related with VEGF expression in our study. In Cox
multivariate analysis only FIGO stage and radiation therapy
duration were significant factors for the survival. We suggest
that to evaluate whether the VEGF expression is an indepen-
dent prognostic factor, further investigation with large num-
ber of patient is warranted.
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